PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases.
PDGF and its receptors are involved in a variety of diseases: cancers, atherosclerosis, balloon injury induced restenosis, pulmonary fibrosis and more. In all cases enhanced signaling of the receptor is the hallmark. In some cases, like chronic monomyelocytic leukemia (CMML), the persistent PDGFR signaling is essential for the survival of the cancer cell. These findings induced the research community as well as the pharmaceutical industry to develop agents that block PDGFR signaling. The possible utilization of PDGFR kinase inhibitors as anti-restenosis agents is likely to move ahead of the utilization of these agents to treat human malignancies.
Levitzki
Alexander
A
Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Givat Ram, 91904 Jerusalem, Israel. levitzki@vms.huji.ac.il
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000201:enzymology; D023903:Coronary Restenosis / Q000188:drug therapy / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008954:Models, Biological; D008956:Models, Chemical; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D011658:Pulmonary Fibrosis / Q000188:drug therapy / Q000201:enzymology; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism
D004791:Enzyme Inhibitors; D010982:Platelet-Derived Growth Factor; C099852:PDGF receptor tyrosine kinase; D017479:Receptors, Platelet-Derived Growth Factor